Prednisol

Quick links to important sections

Prednisol

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prednisol

Property Description
Active Ingredient Prednisolone Acetate
Form Topical Ophthalmic Suspension or Solution
Pharmacological Class Glucocorticoid (Corticosteroid)
General Purpose Managing severe inflammation and immune response
Origin Synthetic

What Type of Medicine is Prednisol?

Prednisol is the trade name for a potent, synthetic pharmaceutical preparation containing the active component Prednisolone Acetate. This compound is classified as a glucocorticoid, belonging to the wider corticosteroid drug class, which are synthetic analogues of steroid hormones naturally produced by the adrenal glands. Prednisolone Acetate is utilized as a single-ingredient formulation and is chemically defined as a pro-drug. This means the initial substance is designed to be highly stable, only becoming fully active as prednisolone once it reaches the specific tissues where it is needed. This conversion feature is clinically recognized for ensuring effective tissue-level delivery, supporting its use over non-esterified forms in certain topical preparations.


Prednisolone Acetate: Form and General Purpose

The medication is specifically prepared as a sterile, topical ophthalmic suspension or solution, intended exclusively for application to the eye, ensuring a highly concentrated local effect. The general purpose of this synthetic medicine is to provide a powerful anti-inflammatory and immunosuppressive action to rapidly manage swelling and inflammation. This preparation is effective in reducing the redness, swelling, and discomfort associated with inflammatory conditions. This characteristic anti-inflammatory power makes it a valuable choice for acute localized conditions, such as reducing post-surgical inflammation following common eye procedures.


Why is Prednisolone Acetate Used as an Ophthalmic Suspension?

The physical formulation as a suspension is the primary distinguishing feature of this preparation compared to simple solutions. The intentional inclusion of fine, undissolved particles of Prednisolone Acetate allows the drug to remain in prolonged contact with the eye's tissues, enabling a steady, localized release of the potent ingredient. This delivery system, pharmacologically affirmed to optimize bioavailability, is crucial for maximizing the therapeutic benefit within the affected area while minimizing systemic exposure and potential effects often associated with orally administered corticosteroids.

Regulatory References

  1. FDA Drug Label

What side effects are possible with Prednisol?

Possible side effects and safety information

The safety profile of Prednisolone Acetate ophthalmic preparations is primarily defined by localized effects within the eye, as documented in official regulatory sources. Specific frequency classifications (e.g., Common or Uncommon) for many adverse reactions may not be universally assigned across all regulatory documents.

Documented Adverse Reactions

The officially documented adverse reactions primarily concern the Eye disorders system and associated Infections and Infestations.

Category Officially Documented Reactions
Common/Expected Transient burning/stinging, foreign body sensation, ocular discomfort.
Serious Risks Elevated Intraocular Pressure (IOP), Glaucoma, Optic Nerve Damage, Posterior Subcapsular Cataract formation, and possible Perforation of the Globe in cases of pre-existing corneal or scleral thinning.

Safety Considerations and Constraints

The risk of serious adverse reactions, notably elevated IOP and cataract formation, is explicitly associated with prolonged use. Conversely, elevated IOP can still occur following short-term administration.

The preparation is subject to specific safety limitations. It is officially restricted from use in most viral diseases of the cornea and conjunctiva, including active Herpes Simplex Keratitis, and in untreated purulent ocular infections, Mycobacterial, and Fungal diseases of the eye structures.

Regarding special populations, regulatory labels note that pediatric patients may have an increased and earlier risk of corticosteroid-induced ocular hypertension. Furthermore, the use of the preparation is associated with the potential for delayed wound healing following certain eye surgeries and may increase the hazard of secondary ocular infections.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations of overdose, regulator-mandated emergency actions, and required supportive measures for Prednisolone Acetate ophthalmic preparations, based strictly on government regulatory sources.


Overdose Scope

Domain Official Regulatory Statement
Documented Overdose Presentations Acute systemic toxicity is unlikely due to the topical ophthalmic route and low concentration. Overuse may lead to an exaggeration of known adverse effects.
Physiological Systems Affected Ocular system, specifically documented for complications such as Ocular Hypertension, Posterior Subcapsular Cataract Formation, and Corneal Ulcers.
Emergency-Response Statements Management must be symptomatic and supportive. No specific antidote is known.

When Immediate Medical Help is Required

Regulatory authorities explicitly state that patients must seek immediate medical attention and/or contact a Poison Control Center following suspected overdose or accidental oral ingestion. This action is mandated to assess potential systemic effects, despite the low systemic absorption associated with the intended topical use.

Connection to the Overall Overdose Profile

The official overdose profile emphasizes that systemic toxicity is considered improbable via the intended local route, focusing attention on local ocular complications that can result from prolonged or excessive use. The required emergency response is procedural, mandating immediate medical contact for specific scenarios like accidental ingestion and confirming that management is limited to symptomatic and supportive treatment.

Therapeutic Uses of Prednisol

This ophthalmic preparation is commonly used across domains where additional symptomatic support is needed to address symptoms related to inflammatory or irritative states in acute clinical situations.

Managing Severe Ocular Inflammation and Relief of Acute Discomfort

This medicine is generally used in situations involving certain distressing symptoms that affect the anterior structures of the eye, such as the cornea, conjunctiva, and iris. It may assist with managing the physical manifestations of inflammation, specifically addressing conditions like iritis, uveitis, and keratitis. The medication contributes to easing the overall symptom load and may assist with managing pronounced tissue swelling and visible redness.

The medication is relevant for easing the symptoms related to physical discomfort that accompany severe inflammation, like intense burning, chronic irritation, pain, and persistent itching. It is applied when groups of symptoms appear suddenly or fluctuate to a point that interferes with daily comfort. This supports the patient during difficult episodes by easing distress when symptoms become temporarily overwhelming.

In clinical settings, it is commonly used to manage the heightened inflammatory response following eye surgeries, such as cataract extraction, and to address inflammation resulting from localized trauma. This use assists with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: Relief for Acute Ocular Discomfort


Regulatory References

  1. NIH DailyMed Drug Label

Eligibility and Restrictions for Use

Prednisol (prednisolone) is a corticosteroid typically prescribed for a wide range of inflammatory and autoimmune conditions, as well as certain cancers and severe allergies. Most adults and children can take the medication, but its use requires careful consideration of the patient’s overall health and pre-existing medical conditions.


Contraindications

Prednisol should not be used by individuals with a known hypersensitivity or allergy to prednisolone or any of its components. Additionally, it is absolutely contraindicated in patients with systemic fungal infections unless the fungal infection is being actively treated.


Required Caution and Consultation

Many other conditions require a physician’s careful judgment and may necessitate dose adjustments or increased monitoring. It is essential to inform your healthcare provider if you have:

  • Active or recent infections (especially chickenpox, measles, shingles, or herpes simplex eye infection), as Prednisol can suppress the immune system.
  • Gastrointestinal disorders such as active peptic ulcer, diverticulitis, or ulcerative colitis, due to the risk of perforation or bleeding.
  • Cardiovascular issues, including high blood pressure (hypertension) or recent heart attack.
  • Metabolic/Endocrine conditions like diabetes, Cushing's syndrome, or thyroid disorders.
  • Ophthalmic conditions such as glaucoma or cataracts.
  • Mental health issues, including severe depression or psychosis.
  • Osteoporosis (thinning bones).

Use during pregnancy or breastfeeding should be discussed with a doctor, as high or prolonged doses may carry risks. Furthermore, patients should avoid certain vaccinations while on Prednisol due to reduced immune response.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Prednisol (Prednisolone Acetate Ophthalmic Suspension) has a localized action, resulting in minimal official documentation of interactions compared to oral corticosteroids. The officially documented interactions primarily concern metabolic effects and local ocular reinforcement, as defined in regulatory prescribing information.


Pharmacokinetic Interaction: Increased Systemic Exposure

Co-treatment with strong CYP3A4 inhibitors may increase the systemic exposure (plasma concentration) of prednisolone. This pharmacokinetic interaction elevates the risk of systemic corticosteroid effects, such as adrenal suppression. The official regulatory advice is to avoid this combination unless the benefit is determined to outweigh the increased risk, necessitating patient monitoring. Medicines documented to be potent CYP3A4 inhibitors include ritonavir and cobicistat.

Pharmacodynamic Interaction: Local Ocular Risk

Concomitant use with other topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for the eye may increase the potential for complications related to corneal healing. This is classified as a local pharmacodynamic interaction.

Population-Specific Consideration

Regulatory documents emphasize that the risk of systemic effects, particularly adrenal suppression from high-dose, frequent, or prolonged use, is a specific consideration for infants and children.

Mechanism of Action

Glucocorticoid Receptor Activation and Genomic Control

The drug's active form, Prednisolone, acts as an agonist by binding to the Cytoplasmic Glucocorticoid Receptor (GR). This interaction initiates the receptor's translocation into the cell nucleus. Once there, the GR complex engages in transrepression and transactivation of genes, thereby suppressing the synthesis of key pro-inflammatory proteins and altering the transcription of genes encoding inflammatory and anti-inflammatory proteins.

Blocking the Core Inflammatory Cascades

A direct consequence of this genomic action is the upregulation of Lipocortin-1, a protein that inhibits the enzyme Phospholipase A2 (PLA2). By halting PLA2, the drug interrupts the Arachidonic Acid Cascade early, preventing the formation of all eicosanoids, including prostaglandins and leukotrienes. This interruption restricts the chemical signals that mediate local vasodilation and capillary permeability.

️ Modulating Immune Cell Traffic and Tissue Effects

Beyond chemical signal suppression, the mechanism reduces the production of adhesion molecules and chemokines, thereby restricting the migration and infiltration of immune cells like neutrophils to the site of inflammation. This control over cellular traffic and mediator release contributes to the reduction of fluid extravasation (edema) in tissues and modulates processes associated with chronic tissue changes, such as fibroblast proliferation and collagen deposition.

Dosage and Administration Information

How Prednisol is Used: Official Administration Guidelines

This section describes the high-level principles for using Prednisol (Prednisolone Acetate Ophthalmic Suspension), based strictly on established procedural information. The administration follows a structured, dose-adjustable protocol that is essential for proper use.


Administration Scope

Feature Official Instruction Summary
Route of Administration Topical Ophthalmic Use only. The medication is instilled directly into the eye.
Dosing Schedule The standard starting dose is one to two drops per affected eye. The dose is subject to stepwise reduction as the treatment course progresses.
Frequency and Timing Initial frequency is typically two to four times a day. In acute, severe cases, this frequency may be increased, but subsequent treatment involves a gradual reduction to a lower daily application for maintenance.
Preparation and Handling The suspension must be shaken well immediately before each use. To prevent contamination, the dropper tip must not touch any surface.
Special Conditions The drop must be placed into the conjunctival sac. Soft contact lenses must be removed prior to application and may only be reinserted after a waiting period of 15 minutes.

Use Duration and Procedural Requirements

Classification Detail Summary
Frequency Pattern Dose-Adjustable Daily use, defined by an initial intense phase followed by scheduled reduction.
Age-Group Rules Use has been established for pediatric patients, with the specific dosage determined by the physician. No overall difference in use has been noted for geriatric patients.
Use-Context Constraint Therapy must not be discontinued prematurely. Re-evaluation is required if the condition does not improve after two days of initial use.

The official protocol is structured by an intense initial delivery method that requires preparation and strict handling, followed by a necessary gradual reduction schedule to complete the intended course.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prednisol

Evidence for Use in Post-Surgical Ocular Inflammation

Research has explored responses over defined time intervals in conditions associated with inflammation following eye procedures like cataract surgery. The study base consists largely of short-term, controlled research studies and analyses of multiple trials, which often included comparisons against a non-active preparation and against other similar drops. These trials focused on tracking changes in objective inflammatory markers, such as the measured status of cells and flare clearance in the eye's anterior chamber, and patient-reported outcomes describing perceived discomfort.

Research highlights changes measured in the status of anterior chamber inflammation markers during the first weeks following surgery. Certain comparative studies reported patterns observed in the measured clearance of inflammation markers when studied against alternative corticosteroid drops. These findings describe patterns observed in the studies and reflect the specific conditions under which they were conducted.


Evidence for Use in Non-Infectious Anterior Segment Inflammatory Disorders

The specific ophthalmic preparation was studied for conditions characterized by fluctuating or episodic manifestations of inflammation, such as endogenous anterior uveitis (iritis). Research examined changes in objective inflammation severity, focusing on the mean change in anterior chamber cell grade. Studies also monitored outcomes reflecting daily functioning or activity level, using patient-reported outcomes to track perceived discomfort.

Research describes patterns of change in objective inflammation scores observed over the study period, which often extended up to six weeks to account for the defined time intervals of the study. Findings from comparative studies exploring different treatment schedules indicated that a higher frequency of drop administration was observed in studies examining patterns related to clearance compared to certain alternative treatments. These findings indicate soft, non-causal patterns related to symptom evolution in the observed populations.


Research Gaps and Remaining Uncertainty

The core clinical trials exploring the pattern related to inflammation were conducted over defined time intervals, typically ranging from a few weeks up to a maximum of six weeks. This acute focus means that long-term effects are not fully established regarding sustained functional outcomes or durability of the pattern related to inflammation status. A key limitation noted in scientific literature is the short-term focus of the initial observation trials. The follow-up durations were limited, meaning that long-term effects are not fully established, particularly for chronic inflammatory conditions. Data for certain specific groups, such as pregnant women or individuals with specific comorbid conditions, remain insufficient.

Key Studies & References

  1. South African National Essential Medicine List Adult Hospital Level Medication Review Process Component: Eye con (Review comparing different steroids in uveitis)

Frequently Asked Questions (FAQ)

Common questions about Prednisol (FAQ)


Q: What are the most common side effects people report when taking Prednisol?

Official product information states that the most commonly reported local adverse reactions are usually transient (temporary) and include a burning or stinging sensation, a feeling like a foreign body is in the eye, and general ocular discomfort. These effects are typically mild and localized to the eye.


Q: Can Prednisol cause blurred vision or eye problems?

Yes, official safety information indicates that both blurry vision and decreased visual acuity (sharpness of vision) have been reported. Furthermore, prolonged use is associated with serious risks, including the formation of cataracts and the development of glaucoma, which can potentially cause optic nerve damage.


Q: Does Prednisol interact with common pain relievers like ibuprofen?

Regulatory documents primarily focus on interactions with other eye drops. Concomitant use with other topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may increase the potential for complications related to corneal healing. Official documentation does not consistently list specific warnings for oral pain relievers like ibuprofen, though warnings exist for topical NSAID eye drops. Patients should always disclose all medications to their doctor.


Q: Does Prednisol make you more susceptible to infections?

Yes, regulatory documents indicate that the prolonged use of this medication may suppress the local immune response in the eye. This effect increases the risk of secondary infections, including those caused by bacteria, fungi, or viruses, such as Herpes Simplex Keratitis.


Q: What are the long-term effects of taking low-dose Prednisol?

Risks associated with prolonged use of this corticosteroid eye drop include glaucoma (elevated pressure inside the eye, or IOP), optic nerve damage, and the formation of a type of cataract called a posterior subcapsular cataract. These risks should be considered even when using the medication over extended periods.


Q: Is it safe to get vaccines while taking Prednisol?

Official warnings state that patients receiving corticosteroid therapy should generally avoid certain vaccinations, particularly those using attenuated (weakened) live viruses. This is because the medication may reduce the immune response to the vaccine.


Q: Can Prednisol be used in children for certain conditions?

Regulatory information confirms that use of this medication is established for pediatric patients; however, children may have an increased and earlier risk of corticosteroid-induced ocular hypertension (high eye pressure). The specific conditions and necessary dosage adjustments are determined by the treating physician.


Q: How soon after starting Prednisol should I expect to see improvement?

Official procedural requirements state that if the patient's condition does not show improvement after two days of initial use, a re-evaluation by a physician is required. This time frame gives a clinical boundary for when the treatment course must be assessed.


Q: What happens if you suddenly stop taking Prednisol?

Official warnings advise against abrupt discontinuation, especially after prolonged use. Stopping suddenly may potentially cause symptoms similar to adrenal insufficiency due to the body's decreased ability to produce its own steroids. The dose should be gradually reduced over time under a physician's care.


Q: Is a metallic taste in the mouth a side effect of Prednisol?

Yes, official adverse event reporting for the ophthalmic suspension has included reports of dysgeusia, which is the medical term for a change in taste or a metallic taste sensation.


Q: Why are people sometimes given Prednisol for allergic reactions?

The general purpose of the active component, prednisolone, is to provide a powerful anti-inflammatory and immunosuppressive action. This action helps to rapidly manage the swelling, redness, and inflammation that are key manifestations of allergic reactions.


Q: What are the signs of a serious, but rare, side effect from Prednisol?

Serious side effects documented in the product label include signs related to elevated Intraocular Pressure (IOP), such as vision defects and potential optic nerve damage. Other serious risks involve the potential for secondary ocular infections and, in cases of pre-existing corneal thinning, possible perforation of the eye globe.


Q: What is the difference between oral Prednisol and injected Prednisol?

The specific product, Prednisol, is prepared as a sterile topical ophthalmic suspension or solution and is intended exclusively for application to the eye. This localized delivery system ensures a high concentration of the drug at the site of inflammation while aiming to minimize the systemic effects often associated with orally administered or injected corticosteroids.


Q: Can short-term use of Prednisol still cause withdrawal symptoms?

While significant withdrawal symptoms are typically associated with prolonged use that leads to adrenal suppression, regulatory guidance still advises that the dose should be gradually reduced and not discontinued abruptly, even after a short course of treatment, to prevent potential negative outcomes.


Q: Is there a generic version of Prednisol available?

Yes, the active ingredient in this medication, prednisolone acetate, is generally available as a generic ophthalmic suspension from various manufacturers, as confirmed by regulatory drug details.

How should Prednisol be stored and disposed of?

How to Store and Dispose of Prednisol

Storage and disposal of Prednisol (prednisolone acetate ophthalmic suspension) must adhere to official regulatory requirements to maintain product integrity and safety.


Official Storage Conditions

Requirement Condition
Temperature Store below 30 C; Do not freeze.
Protection Protect from light and keep the bottle tightly closed.
Handling Shake well before using to ensure uniform suspension.
Child Safety Keep out of the reach and sight of children.

Disposal Instructions

Unused or expired Prednisol must not be thrown away via wastewater or household waste. Disposal must be performed according to local regulations as advised by a pharmacist or local authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prednisol found in:

A-Z Index: